16-ISABC · Ioannina 2023

Metallodrugs against antimicrobial resistance: emerging frontiers

The accelerating crisis of antimicrobial resistance has outpaced the development pipeline of conventional antibiotics, leaving clinicians with dwindling options against infections that were once routine. Bacteria such as methicillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa now claim millions of lives globally each year. Against this backdrop, metal-based compounds are being re-evaluated as a versatile and mechanistically distinct class of therapeutics.

Australia has positioned itself at the forefront of resistance research, with the Therapeutic Goods Administration tightening antimicrobial stewardship requirements and the National Health and Medical Research Council directing substantial funding toward novel therapeutic discovery. Sydney, Melbourne, and Brisbane host research clusters that bridge bioinorganic chemistry, microbiology, and clinical pharmacology, establishing the country as a meaningful contributor to the global metallodrug conversation.

The case for metal-based antimicrobials

Metallodrugs offer several attributes that conventional organic molecules cannot easily replicate. Their redox activity, tunable coordination geometries, and capacity to engage multiple bacterial targets simultaneously make them difficult for pathogens to evade through single-point mutations. Silver, copper, zinc, ruthenium, gallium, and bismuth complexes have all demonstrated activity against strains that resist frontline antibiotics, reopening a therapeutic space many considered closed.

Beyond direct bactericidal action, certain metal compounds modulate host immune responses or disrupt biofilm matrices that shield bacterial communities from immune clearance. This polypharmacology resonates with Australian researchers pursuing One Health frameworks that integrate human, animal, and environmental reservoirs of resistance, particularly in remote and Indigenous community settings where infection control resources are constrained.

Interest in bioinorganic therapeutics has built upon earlier gatherings such as the international porphyrin symposium that helped legitimise metal-organic research in pharmacological contexts. Those meetings seeded the international networks that later symposia, including the present gathering in Ioannina, continue to nurture.

Comparing leading metallodrug classes

The diversity of metal complexes under investigation reflects the breadth of mechanistic possibilities they offer. Researchers comparing candidate scaffolds evaluate factors such as spectrum of activity, toxicity profiles, and feasibility of synthesis at scale. Coordination chemists, microbiologists, and pharmacologists now collaborate more closely than ever to identify which scaffolds deserve progression toward clinical evaluation.

Class Primary mechanism Notable resistant targets Development status
Silver(I) complexes Membrane disruption, ROS generation MRSA, P. aeruginosa Clinical trials
Ruthenium(II) polypyridyls DNA binding, topoisomerase inhibition Gram-positive cocci Preclinical
Gallium(III) compounds Iron-pathway mimicry P. aeruginosa, S. aureus biofilms Phase I/II
Bismuth subsalicylate derivatives Enzyme inhibition, biofilm interference H. pylori, MDR gut flora Approved indications

These families are not exhaustive, but they illustrate how a single metal centre can be engineered to address different bacterial vulnerabilities. Silver complexes remain the most clinically advanced, while gallium therapeutics have attracted Australian biotech investment owing to their activity against chronic lung infections prevalent in cystic fibrosis cohorts treated in Brisbane and Perth.

Australian research driving the field forward

The Australian Antimicrobial Resistance Network and CSIRO's antimicrobial resistance programme have fostered collaborations spanning university laboratories in Perth, Adelaide, and Hobart with hospital microbiology units. NHMRC project grants have funded translational studies examining gallium nitrate against chronic lung infections, while Melbourne-based groups have explored ruthenium complexes as adjuvants that restore sensitivity to existing antibiotics.

Industry-academic partnerships have also matured, with Australian biotech firms licensing metallodrug candidates for further development. These ecosystems benefit from informal knowledge exchange at events like the networking breakfast hosted alongside major symposia, where senior bioinorganic chemists mentor emerging investigators across career stages.

Mechanisms of action against resistant pathogens

Metal complexes attack bacteria through several convergent routes that bypass classical resistance determinants. Cationic silver and copper species disrupt membrane integrity, generating reactive oxygen species that overwhelm bacterial antioxidant defences. Ruthenium compounds intercalate into DNA or inhibit essential enzymes, while gallium sabotages iron acquisition pathways critical for biofilm-resident bacteria by mimicking ferric iron.

These mechanisms are particularly relevant against persisters and intracellular pathogens that conventional antibiotics struggle to reach. Australian groups studying Q fever (Coxiella burnetii) and melioidosis (Burkholderia pseudomallei), both endemic to the tropical north, have noted that metallodrug scaffolds may finally offer intracellular activity sufficient to clear latent infections.

Mechanistic strengths of leading metallodrug classes include:

Regulatory landscapes and translation pathways

Bringing a metallodrug to market requires navigating regulatory frameworks that were largely designed for small organic molecules. The Therapeutic Goods Administration evaluates metal-containing compounds on a case-by-case basis, often requiring additional data on speciation, metabolic fate, and accumulation in tissues such as bone or liver. The Pharmaceutical Benefits Scheme then weighs cost-effectiveness against existing reimbursed therapies.

Researchers are increasingly designing metallodrugs with regulatory clarity in mind, favouring ligands that yield stable, well-characterised complexes. Coordinated discussions among regulators, academic chemists, and clinical pharmacologists are shortening feedback loops and helping Australian investigators align early-stage designs with downstream expectations.

Key considerations for clinical translation of metallodrugs include:

Connecting research communities at ISABC 2023

The 16th International Symposium on Applied Bioinorganic Chemistry in Ioannina provides a fitting venue for advancing the antimicrobial metallodrug conversation. Sessions will explore synthesis, mechanism, and translation, with dedicated forums for early-career chemists who often drive methodological innovation. The symposium also offers continuity with earlier bioinorganic gatherings, sustaining the international networks that underpin collaborative grant applications and student exchanges.

Delegates interested in presenting original work can prepare contributions through the abstract submission portal, where submissions are evaluated by the scientific committee ahead of the June programme. Topics spanning metal-peptide conjugates, photoactivatable complexes, and metallo-antibiotics will find welcoming audiences across the symposium's themed sessions.

Register through the official Zita Congress secretariat, secure accommodation early, and prepare a contribution that advances the field. Bring your data, your collaborators, and your perspective to Ioannina this June. The conversations that begin in those halls will determine which metallodrug scaffolds progress toward Australian clinics over the coming decade, building on momentum already established across the country's research-intensive universities.